2017
Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer
Boland PM, Meyer JE, Berger AC, Cohen SJ, Neuman T, Cooper HS, Olszanski AJ, Davey M, Cheng JD, Lebenthal A, Burtness BA, Scott WJ, Astsaturov IA. Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer. American Journal Of Clinical Oncology 2017, 40: 393-398. PMID: 26986978, PMCID: PMC5026539, DOI: 10.1097/coc.0000000000000171.Peer-Reviewed Original ResearchConceptsGastroesophageal junction carcinomaPreoperative chemoradiationPreoperative chemotherapyAdditional patientsSmall molecule receptor tyrosine kinase inhibitorGrade 4 nonhematologic toxicityReceptor tyrosine kinase inhibitorsPhase ICommon acute toxicitiesLocalized esophageal cancerResectable esophagogastric cancerTolerability of vandetanibMedian overall survivalMicroscopic residual diseasePathologic complete responseLocalized esophageal carcinomaTyrosine kinase inhibitorsEsophagogastric cancerInduction therapyNonhematologic toxicityPrior therapyDaily radiotherapyLate complicationsOverall survivalSurgical candidates
2010
Molecular selection for 'smart' study design in lung cancer
Psyrri A, Burtness B. Molecular selection for 'smart' study design in lung cancer. Nature Reviews Clinical Oncology 2010, 7: 621-622. PMID: 20981127, DOI: 10.1038/nrclinonc.2010.156.Peer-Reviewed Original Research